Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Efficacy and Safety Study of IFX-1 in Add-On to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

NCT03712345 is registered in ClinicalTrials.gov with InflaRx GmbH as lead sponsor.

NCT NCT03712345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03712345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Efficacy and Safety Study of IFX-1 in Add-On to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
Lead sponsor
InflaRx GmbH
Phase
Phase 2
Overall status
Terminated
Start date
October 15, 2018
Completion date
May 3, 2021
Enrollment
20 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

granulomatosis with polyangiitis (gpa), microscopic polyangiitis (mpa)